Trial offering new treatment combination for melanoma brain metastases
The BETTER trial, recently activated in Australia, is testing a new treatment combination for melanoma that has spread to the brain, with the goal of improving outcomes for patients facing a poor prognosis and life expectancy. It examines a combined treatment of immunotherapy drugs nivolumab and ipilimumab with bevacizumab and targeted radiotherapy. The trial will evaluate the safety and efficacy of the treatment combination, potentially offering new hope for those with advanced melanoma.